Efficacy and safety of josamycin in patients with nonsevere communityacquired pneumonia in routine clinical practice: results of a prospective multicenter observational program

Aim. A goal of this noninterventional prospective multicenter observational program was to evaluate efficacy and safety of josamycin in patients with nonsevere communityacquired pneumonia (CAP) in routine clinical practice.

Methods. Patients (n = 104) with radiological signs of pneumonia were treated with josamycin (Wilprafen® Solutab®, dispersible tablets 1 000 mg). Complete resolution of CAP was achieved in 95.6 % of patients, a clinically significant improvement was seen in 3.3 % of patients and a lack of effect was seen in 1 (1.1 %) patient. Radiological followup did not reveal worsening in any patients.

The results of this study have demonstrated that josamycin was highly effective (> 95 %) and had a good safety profile in outpatients with nonsevere CAP.

1. Chuchalin A.G., Sinopal'nikov A.I., Kozlov R.S. et al. Communityacquired pneumonia in adults. Practical guidelines on diagnosis, treatment and prevention. Moscow; 2010 (in Russian).

2. Bilichenko T.N., Chuchalin A.G., Son I.M. General results of specialized medical aid for patients with pulmonary disease in Russian Federation in 2004–2010. Pul'monologiya. 2012; 3: 5–16 (in Russian).

3. Leshchenko I.V. Macrolides and communityacquired pneumonia. A physician gets a choice. Prakticheskaya pul'monologiya. 2014; 1:15–21 (in Russian).

4. Sinopal'nikov A.I. Communityacquired pneumonia in adults. Consilium Medicum. 2007; 9 (3): 516 (in Russian).

5. Freifeld A.G., Bow E.J., Sepkowitz K.A. et al. Clinical practiceguideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2011; 52 (4): e56–93.

6. Prokhorovich E.A. Communityacquired pneumonia. Meditsinskiy sovet. 2012; 1: 12–19 (in Russian).

7. Karagodina Yu.Ya., Zakharova N.K., Kholod O.L. et al. Safety and efficacy of novel formulation of josamycin in adult patients with respiratory infection: Results of a prospective observational study. Pul'monologiya. 2009; 5: 98–106 (in Russian).

8. Belousov Yu.B., Sinopal'nikov A.I., Yakovlev S.V. et al. efficacy and safety of josamycin in patients with nonsevere community acquired pneumonia. Results if a multicenter clinical trial. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2007; 9 (1): 48–56 (in Russian).

9. MalhotraKumar S., Lammens C., Coenen S. et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolideresistant streptococci in healthy volunteers: a randomised, doubleblind, placebocontrolled study. Lancet. 2007; 369 (9560): 482–490.

10. Sidorenko S.V., Volkova M.O., Kalinogorskaya O.S. et al. Antibacterial resistance of Streptococcus pneumonia: clinical significance and a tendency to spread. Vestnik prakticheskogo vracha. 2014; 2 (3):9–15 (in Russian).

11. Rollins D., Good J. Jr, Martin R. The role of atypical infections and macrolide therapy in patients with asthma. J. Allergy Clin. Immunol. Pract. 2014; 2 (5): 511–517.

12. Yakovlev S.V., Dovgan' E.V. Aspects of antibacterial efficacy. Spravochnik poliklinicheskogo vracha. 2014; 6: 4–6 (in Russian).

13. Tatochenko V.K. Josamycin in pediatrics. Pediatriya. 2011; 90 (5): 124–128 (in Russian).

14. Yakovlev S.V., Rafal'skiy V.V., Sidorenko S.V. et al. Strategy of Rational Antibacterial Therapy in Outpatients: Russian PracticalGuidelines. Moscow: Presto print; 2014 (in Russian).

15. A leaflet on Wilprafen® Solutab®. Drug registration number is LS001632020811 (in Russian).

16. Lovmar M., Vimberg V., Lukk E. et al. Cisacting resistance peptides reveal dual ribosome inhibitory action of the macrolide josamycin. Biochimie. 2009; 91 (8): 989–995.

17. Zhao Z., Jin L., Xu Y. et al. Synthesis and antibacterial activity of a series of novel 9Oacetyl 4'substituted 16membered macrolides derived from josamycin. Bioorg. Med. Chem. Lett. 2014; 24 (2):480–484.